+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Antifungal Drugs: Technologies and Global Markets

  • ID: 5027809
  • Report
  • May 2020
  • Region: Global
  • 291 Pages
  • BCC Research
1 of 4

FEATURED COMPANIES

  • Astellas Pharma Inc.
  • Cidara Therapeutics Inc.
  • Galderma Pharma S.A.
  • Leadiant Biosciences Inc.
  • Moberg Pharma Ab
  • Pfizer Inc.
  • MORE

Report Scope:

The aim of this report is to initially conduct a review of the antifungal drugs currently available, explore the issues facing the use of antifungal drugs and review some of the latest developments of new and innovative antifungal drugs, their technologies and their intended clinical applications. The key objective is also to conduct and provide an analysis of the market value, growth rates, market shares and market development, and examine the market dynamics and market factors influencing the growth and development of this market.

This report also looks at the challenges and potential threats facing the industry and the factors influencing the market shares of the major market suppliers as well as smaller manufacturers in local markets.

The emphasis of this report is to provide the reader with:

  • A detailed analysis of the revenues and forecasts for the global antifungal drug market with a more-detailed analysis and forecast of the revenues for the global market sub-divided by major market sub-segments by geographic region and selected country.
  • A detailed analysis of the global market share together with a more detailed analysis of the market share by geographic regions and selected country.

In addition, this analysis provides:

  • Detailed review of the current products, their indications and availability for all the market segments identified.
  • Profile of the individual market sub-segments within the major market segments analyzed and the distinguishing features of each of the market sub-segments.
  • Review of the major market opportunities through the recognition of specific high-growth and emerging market opportunities.
  • Brief description of the historical development for each of the major market segments.
  • Profile of the leading suppliers of antifungal drugs together with related information about specific products.

The study will allow the reader to:

  • Evaluate the effect of strategic factors such as technology-driven change and industry consolidation for the antifungal drug market.
  • Investigate the current market dynamics that are driving change in the antifungal drug market.
  • Assess future growth opportunities in the antifungal drug market.
  • Review the main products in each sector and plan a product entry strategy in line with the strengths and weaknesses of the competition.
  • Realize an individual company’s position in the market and to gain insight into the future of the market and the opportunities that exist.

The analysis includes the use of charts and graphs measuring product growth and trends within the marketplace. Company-specific information, including sales figures, product pipeline status and R&D trends, is provided throughout the report.

Report Includes:

  • 116 data tables and 27 additional tables
  • An overview of the global markets for antifungal drugs within the pharmaceuticals industry
  • Analyses of the global market trends, with data corresponding to market size from 2018 and 2019, and projections of compound annual growth rates (CAGRs) through 2024
  • Comparative study of the two primary segments of antifungal medications – over-the-counter (OTC) and prescription based – and issues facing the use of these products
  • Briefing about therapeutics in early development such as new molecular and biological entities from traditional pharmaceutical sources, naturally derived synthetic chemicals, and biological sources
  • Review of antifungal agents and their classification based on the mechanism of action, approved therapeutic products and relevant patents with their expiration dates
  • Information pertaining to R&D efforts, breakthrough therapy innovations, clinical trials of novel drug developments, their technologies and intended clinical applications
  • Market share analysis of leading suppliers of antifungal drugs with related information about specific products, and their key competitive landscape
  • Descriptive company profiles of major market players, including Astellas Pharma Inc., Bayer AG, Dr. Reddy's Laboratories Ltd., Gilead Sciences Inc., Janssen Pharmaceuticals Inc. (Johnson & Johnson), Pfizer Inc., Sanofi S.A., and Merck & Co., Inc.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Astellas Pharma Inc.
  • Cidara Therapeutics Inc.
  • Galderma Pharma S.A.
  • Leadiant Biosciences Inc.
  • Moberg Pharma Ab
  • Pfizer Inc.
  • MORE

Chapter 1 Introduction

  • Introduction
  • Scope of the Report
  • Methodology and Information Sources
  • Primary Data and Information Gathering
  • Secondary Data and Information Gathering
  • Market Revenue Forecasts
  • Geographic Breakdown
  • Analyst's Credentials
  • Custom Research
  • Related Reports

Chapter 2 Summary and Highlights

  • Global Market Revenue Analysis for Antifungal Drugs
  • Regional Overview
  • Market Segment Review
  • Market Dynamics
  • Market Drivers
  • Market Restraints
  • Market Share Analysis

Chapter 3 Introduction to Fungi and the Antifungal Drug Market

  • Introduction to Fungi
  • Classification of Fungi
  • Chytridiomycota
  • Blastocladiomycota
  • Neocallimastigomycota
  • Microsporidia
  • Ascomycota (Sac Fungi)
  • Basidiomycota (Club Fungi)
  • Glomeromycota
  • Scope of Application: Human Healthcare
  • Types and Descriptions of Fungi Diseases in Humans
  • Aspergillosis
  • Blastomycosis
  • Candidiasis
  • Coccidioidomycosis (Valley Fever)
  • Coccidioidomycosis (Cryptococcosis)
  • Dermatophytosis
  • Fungal Infections of the Eye
  • Histoplasmosis
  • Onychomycosis (Fungal Nail Infections)
  • Mucormycosis (Zygomycosis)
  • Mycetoma
  • Paracoccidioidomycosis
  • Pneumocystis Pneumonia
  • Pseudallescheriasis
  • Sporotrichosis
  • Rare Fungal Infections and Disorders
  • Risk Factors Associated with Human Fungal Infections
  • Use of Antibiotics
  • Use of Corticosteroids
  • Specific Medical Conditions
  • Central Line-Associated Bloodstream Infections
  • Surgery
  • Organ Transplantation
  • Environmental Factors
  • Hereditary Factors
  • Hospitalization

Chapter 4 Common Environmental Fungi

  • Molds and the Human Issues Associated with Them
  • Why Environmental Mold is a Unique Problem
  • Health Risks due to Environmental Fungi and Mold
  • Environmental Molds
  • Alternaria
  • Aspergillus
  • Cladosporium
  • Penicillium
  • Eurotium
  • Rhizopus
  • Mucor
  • Geotrichum
  • Fusarium
  • Stachybotrys
  • Wallemia
  • Trichothecium
  • Scopulariopsis Brevicaulis
  • Scytalidium Dimidiatum
  • Trichoderma
  • Paecilomyces Variotii

Chapter 5 Review of Antifungal Agents

  • Introduction to Antifungal Agents
  • Classification of Antifungal Agents
  • Systemic Antifungal Drugs
  • Polyene Antibiotics
  • Azole Antifungals
  • Echinocandins
  • Antimetabolite: Flucytosine (5-FC)
  • Other Systemic Antifungal Agents
  • Topical Antifungal Drugs
  • Topical Polyene Antibiotics
  • Azoles-Imidazole
  • Others
  • Naturally Occurring Alternatives

Chapter 6 New and Innovative Antifungals: Current Developments, Clinical Trials and Product Pipelines

  • The Need for New and Innovative Antifungals
  • Strategic Approach to the Development of New Antifungal Agents
  • Identification of Bioactive Compounds
  • Nanostructured Antifungals
  • Drug Repositioning
  • Vaccine Development Against Fungal Diseases
  • Artificial Intelligence-Based Platform Technology (FungalAi)
  • Emerging Targets and Molecular Scaffolds
  • New Antifungal Drugs in Development
  • Most Notable Antifungal Compounds
  • Specific Company Product Pipelines
  • Mycovia Pharmaceuticals
  • Amplyx Pharmaceuticals
  • F2G
  • NovaBiotics Ltd.
  • Appili Therapeutics Inc.
  • Scynexis Inc.
  • Bright Angel Therapeutics
  • Valley Fever Solutions

Chapter 7 Global Market for Antifungal Medications

  • Introduction
  • Market Revenue Analysis
  • Global Market Revenue Analysis
  • Regional Overview
  • Major Developments and Trends in Antifungal Drug Treatment and Technologies
  • Prescription Antifungal Drugs
  • OTC Antifungal Drugs
  • Market Share Analysis

Chapter 8 North American Market for Antifungal Drugs

  • Introduction
  • Regulatory and Legislative Requirements
  • United States
  • Canada
  • Market Dynamics
  • Market Drivers
  • Market Restraints
  • Market Analysis
  • North America Market Revenue Analysis
  • Regional Overview
  • Individual Markets
  • Market Share Analysis

Chapter 9 European Market for Antifungal Drugs

  • Introduction
  • Regulatory and Legislative Requirements
  • Mutual Recognition Procedure
  • Centralized Procedure
  • Decentralized Procedure
  • European Suspension of Marketing Authorizations for Oral Ketoconazole
  • Over-the-Counter Antifungal Drug Products
  • The Russian Federation
  • Market Dynamics
  • Market Drivers
  • Market Restraints
  • Market Analysis
  • Market Revenue Analysis
  • Regional Overview
  • Individual Markets
  • Market Share Analysis

Chapter 10 Asia-Pacific Market for Antifungal Drugs

  • Introduction
  • Regulatory and Legislative Requirements
  • Japan
  • China
  • India
  • South Korea
  • Market Dynamics
  • Market Drivers
  • Market Restraints
  • Market Analysis
  • Market Revenue Analysis
  • Regional Overview
  • Individual Markets
  • Market Share Analysis

Chapter 11 Latin American Market for Antifungal Drugs

  • Introduction
  • Regulatory and Legislative Requirements
  • Brazil
  • Argentina
  • Mexico
  • Market Dynamics
  • Market Drivers
  • Market Restraints
  • Market Analysis
  • Market Revenue Analysis
  • Regional Overview
  • Individual Markets
  • Market Share Analysis

Chapter 12 Middle Eastern/African Market for Antifungal Drugs

  • Introduction
  • Regulatory and Legislative Requirements
  • South Africa
  • Saudi Arabia
  • Market Dynamics
  • Market Drivers
  • Market Restraints
  • Market Analysis
  • Market Revenue Analysis
  • Regional Overview
  • Individual Markets
  • Market Share Analysis

Chapter 13 Company Profiles

  • Introduction
  • Tier 1: Manufacturers of Prescription Pharmaceuticals
  • Anacor Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • Bausch Health Companies Inc.
  • Bayer Ag
  • Cidara Therapeutics Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Enzon Pharmaceuticals, Inc.
  • Ferrer Internacional S.A.
  • Galderma Pharma S.A.
  • Gilead Sciences Inc.
  • Glenmark Pharmaceuticals Ltd.
  • Janssen Pharmaceuticals Inc. (Johnson & Johnson)
  • Leadiant Biosciences Inc.
  • Merck & Co., Inc.
  • Merz Pharma Gmbh & Co. Kgaa
  • Moberg Pharma Ab
  • Mylan Laboratories Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Taro Pharmaceutical Industries Ltd.
  • Teva Pharmaceuticals Industries Ltd.

Chapter 14 Appendix A

  • Tier 1: Large Multinational Companies and Leading Market Share Holders
  • Company Contact Details

Chapter 15 Appendix B

  • Tier 2: Entrepreneurial Small and Medium-Sized Enterprises
  • Company Addresses and Contact Details

Chapter 16 Appendix C

  • Research Studies in the Design of Antifungal Vaccine Strategy

Chapter 17 Appendix D

  • Government Regulatory Agencies, Professional Organizations and Regulatory Acronyms

Chapter 18 Appendix E

  • Commonly Used Acronyms and Terms used for Antifungal Drugs and Antifungal Drug Treatments

List of Tables
Summary Table A: Global Market for Prescription Antifungal Drugs, by Type, Through 2024
Summary Table B: Global Market for Antifungal Drugs, by Region, Through 2024
Summary Table C: Global Market for Antifungal Drugs, by Segment, Through 2024
Summary Table D: Global Market Shares of Antifungal Drugs, by Region, 2019
Summary Table E: Global Market for OTC Antifungal Drugs, by Type, Through 2024
Summary Table F: Global Market Shares of Antifungal Drugs, by Company, 2019
Table 1: Statistics on the Ten Most Significant Invasive Fungal Infections
Table 2: Major Clinical Manifestations of Histoplasmosis and Associated Risk Factors
Table 3: Morphologic Features of Fungi and Pseudofungal Infections of Unusual Fungi or of Fungi with Uncertain Etiology
Table 4: Risk Factors Associated with Human Fungal Infections
Table 5: Common Symptoms Associated with Environmental Fungi and Molds
Table 6: Risk Factors Associated with Environmental Fungi and Molds
Table 7: Common Locations of the Sources of Environmental Molds
Table 8: History of Antifungal Therapy
Table 9: Patents on Amphotericin B and Their Expiration Dates
Table 10: Approved Fluconazole Prescription Products
Table 11: Patents on Itraconazole and Their Expiration Dates
Table 12: Patents on Voriconazole and Their Expiration Dates
Table 13: Approved Voriconazole Prescription Products
Table 14: Patents on Posaconazole and Their Expiration Dates
Table 15: Patents on Ketoconazole and Their Expiration Dates
Table 16: Approved Miconazole OTC Products
Table 17: International Clotrimazole Brand Names
Table 18: Approved Generic Prescriptions for Clotrimazole
Table 19: Patents on Caspofungin and Their Expiration Dates
Table 20: Patents on Micafungin and Their Expiration Dates
Table 21: Patents on Anidulafungin and Their Expiration Dates
Table 22: Antifungal Compounds with Novel Targets in Development
Table 23: Global Market for Antifungal Drugs, by Segment, Through 2024
Table 24: Global Market for Antifungal Drugs, by Region, Through 2024
Table 25: Global Market Shares of Antifungal Drugs, by Region, 2019
Table 26: Global Market Shares of Antifungal Drugs, by Company, 2019
Table 27: North American Market for Antifungal Drugs, by Segment, Through 2024
Table 28: North American Market for Prescription Antifungal Drugs, by Type, Through 2024
Table 29: North American Market for OTC Antifungal Drugs, by Type, Through 2024
Table 30: North American Market for Antifungal Drugs, by Country, Through 2024
Table 31: U.S. Market for Antifungal Drugs, by Segment, Through 2024
Table 32: U.S. Market for Prescription Antifungal Drugs, by Type, Through 2024
Table 33: U.S. Market for OTC Antifungal Drugs, by Type, Through 2024
Table 34: Canadian Market for Antifungal Drugs, by Segment, Through 2024
Table 35: Canadian Market for Prescription Antifungal Drugs, by Type, Through 2024
Table 36: Canadian Market for OTC Antifungal Drugs, by Type, Through 2024
Table 37: North American Market Shares of Antifungal Drugs, by Company, 2019
Table 38: European Market for Antifungal Drugs, by Segment, Through 2024
Table 39: European Market for Prescription Antifungal Drugs, by Type, Through 2024
Table 40: European Market for OTC Antifungal Drugs, by Type, Through 2024
Table 41: European Market for Antifungal Drugs, by Country, Through 2024
Table 42: French Market for Antifungal Drugs, by Segment, Through 2024
Table 43: French Market for Prescription Antifungal Drugs, by Type, Through 2024
Table 44: French Market for OTC Antifungal Drugs, by Type, Through 2024
Table 45: German Market for Antifungal Drugs, by Segment, Through 2024
Table 46: German Market for Prescription Antifungal Drugs, by Type, Through 2024
Table 47: German Market for OTC Antifungal Drugs, by Type, Through 2024
Table 48: Italian Market for Antifungal Drugs, by Segment, Through 2024
Table 49: Italian Market for Prescription Antifungal Drugs, by Type, Through 2024
Table 50: Italian Market for OTC Antifungal Drugs, by Type, Through 2024
Table 51: Spanish Market for Antifungal Drugs, by Segment, Through 2024
Table 52: Spanish Market for Prescription Antifungal Drugs, by Type, Through 2024
Table 53: Spanish Market for OTC Antifungal Drugs, by Type, Through 2024
Table 54: U.K. Market for Antifungal Drugs, by Segment, Through 2024
Table 55: U.K. Market for Prescription Antifungal Drugs, by Type, Through 2024
Table 56: U.K. Market for OTC Antifungal Drugs, by Type, Through 2024
Table 57: Benelux Market for Antifungal Drugs, by Segment, Through 2024
Table 58: Benelux Market for Prescription Antifungal Drugs, by Type, Through 2024
Table 59: Benelux Market for OTC Antifungal Drugs, by Type, Through 2024
Table 60: Scandinavian Market for Antifungal Drugs, by Segment, Through 2024
Table 61: Scandinavian Market for Prescription Antifungal Drugs, by Type, Through 2024
Table 62: Scandinavian Market for OTC Antifungal Drugs, by Type, Through 2024
Table 63: Rest-of-European Market for Antifungal Drugs, by Segment, Through 2024
Table 64: Rest-of-European Market for Prescription Antifungal Drugs, by Type, Through 2024
Table 65: Rest-of-European Market for OTC Antifungal Drugs, by Type, Through 2024
Table 66: European Market Shares of Antifungal Drugs, by Company, 2019
Table 67: Overview of Healthcare in India
Table 68: Asia-Pacific Market for Antifungal Drugs, by Segment, Through 2024
Table 69: Asia-Pacific Market for Prescription Antifungal Drugs, by Type, Through 2024
Table 70: Asia-Pacific Market for OTC Antifungal Drugs, by Type, Through 2024
Table 71: Asia-Pacific Market for Antifungal Drugs, by Country, Through 2024
Table 72: Indian Market for Antifungal Drugs, by Segment, Through 2024
Table 73: Indian Market for Prescription Antifungal Drugs, by Type, Through 2024
Table 74: Indian Market for OTC Antifungal Drugs, by Type, Through 2024
Table 75: Chinese Market for Antifungal Drugs, by Segment, Through 2024
Table 76: Chinese Market for Prescription Antifungal Drugs, by Type, Through 2024
Table 77: Chinese Market for OTC Antifungal Drugs, by Type, Through 2024
Table 78: Japanese Market for Antifungal Drugs, by Segment, Through 2024
Table 79: Japanese Market for Prescription Antifungal Drugs, by Type, Through 2024
Table 80: Japanese Market for OTC Antifungal Drugs, by Type, Through 2024
Table 81: South Korean Market for Antifungal Drugs, by Segment, Through 2024
Table 82: South Korean Market for Prescription Antifungal Drugs, by Type, Through 2024
Table 83: South Korean Market for OTC Antifungal Drugs, by Type, Through 2024
Table 84: Rest of Asia-Pacific Market for Antifungal Drugs, by Segment, Through 2024
Table 85: Rest of Asia-Pacific Market for Prescription Antifungal Drugs, by Type, Through 2024
Table 86: Rest of Asia-Pacific Market for OTC Antifungal Drugs, by Type, Through 2024
Table 87: Asia-Pacific Market Shares of Antifungal Drugs, by Company, 2019
Table 88: Latin American Market for Antifungal Drugs, by Segment, Through 2024
Table 89: Latin American Market for Prescription Antifungal Drugs, by Type, Through 2024
Table 90: Latin American Market for OTC Antifungal Drugs, by Type, Through 2024
Table 91: Latin American Market for Antifungal Drugs, by Country, Through 2024
Table 92: Argentinian Market for Antifungal Drugs, by Segment, Through 2024
Table 93: Argentinian Market for Prescription Antifungal Drugs, by Type, Through 2024
Table 94: Argentinian Market for OTC Antifungal Drugs, by Type, Through 2024
Table 95: Brazilian Market for Antifungal Drugs, by Segment, Through 2024
Table 96: Brazilian Market for Prescription Antifungal Drugs, by Type, Through 2024
Table 97: Brazilian Market for OTC Antifungal Drugs, by Type, Through 2024
Table 98: Chilean Market for Antifungal Drugs, by Segment, Through 2024
Table 99: Chilean Market for Prescription Antifungal Drugs, by Type, Through 2024
Table 100: Chilean Market for OTC Antifungal Drugs, by Type, Through 2024
Table 101: Mexican Market for Antifungal Drugs, by Segment, Through 2024
Table 102: Mexican Market for Prescription Antifungal Drugs, by Type, Through 2024
Table 103: Mexican Market for OTC Antifungal Drugs, by Type, Through 2024
Table 104: Rest of Latin American Market for Antifungal Drugs, by Segment, Through 2024
Table 105: Rest of Latin American Market for Prescription Antifungal Drugs, by Type, Through 2024
Table 106: Rest of Latin American Market for OTC Antifungal Drugs, by Type, Through 2024
Table 107: Latin American Market Shares of Antifungal Drugs, by Company, 2019
Table 108: Number of Saudi Arabian Hospitals and Beds, by Sector and Administrative Region
Table 109: Middle Eastern/African Market for Antifungal Drugs, by Segment, Through 2024
Table 110: Middle Eastern/African Market for Prescription Antifungal Drugs, by Type, Through 2024
Table 111: Middle Eastern/African Market for OTC Antifungal Drugs, by Type, Through 2024
Table 112: Middle Eastern/African Market for Antifungal Drugs, by Region/Country, Through 2024
Table 113: African Market for Antifungal Drugs, by Segment, Through 2024
Table 114: African Market for Prescription Antifungal Drugs, by Type, Through 2024
Table 115: African Market for OTC Antifungal Drugs, by Type, Through 2024
Table 116: Middle Eastern Market for Antifungal Drugs, by Segment, Through 2024
Table 117: Middle Eastern Market for Prescription Antifungal Drugs, by Type, Through 2024
Table 118: Middle Eastern Market for OTC Antifungal Drugs, by Type, Through 2024
Table 119: Middle Eastern/African Market Shares of Antifungal Drugs, by Company, 2019
Table 120: Astellas Pharma Inc.: Revenues, by Drug, 2017-2019
Table 121: Bausch Health Companies Inc.: Revenues, by Segment, 2017-2019
Table 122: Bayer AG: Revenues, by Division, 2017-2019
Table 123: Bayer AG: Revenues, by Best Selling Products in the Consumer Health Division, 2018-2019
Table 124: Cidara Therapeutics Inc.: Revenues, by Type, 2016-2019
Table 125: Dr. Reddy's Laboratories: Revenues, by Region and Division, 2017-2019
Table 126: Gilead Sciences Inc.: Revenues, by Product Segment, 2016-2019
Table 127: Merck & Co., Inc.: Revenues, by Antifungal Product Segment, 2016-2019
Table 128: Mylan Laboratories Inc.: Revenues, by Segment, 2016-2019
Table 129: Pfizer Inc.: Revenues, by Segment, 2017-2019
Table 130: Vfend: Revenues, by Product Segment, 2017-2019
Table 131: Sanofi S.A.: Revenues, by Segment, 2017-2019
Table 132: Teva Pharmaceutical Industries Ltd.: Revenues, 2017-2019
Table 133: Tier 1: Major Multinational Medical Device Companies: Contact Details
Table 134: Tier 2: Entrepreneurial Small and Medium-Sized Enterprises Contact Details
Table 135: Studies Conducted in the Design of Antifungal Vaccine Strategy
Table 136: Government Regulatory Agencies, Professional Organizations and Regulatory Acronyms
Table 137: Commonly Used Acronyms and Terms used for Antifungal Drugs and Antifungal Drug Treatments

List of Figures
Summary Figure A: Global Market for Antifungal Drugs, by Segment, 2018-2024
Summary Figure B: Global Market for Antifungal Drugs, by Region, 2018-2024
Summary Figure C: Global Market Shares of Antifungal Drugs, by Region, 2019
Summary Figure D: Global Market for Prescription Antifungal Drugs, by Type, 2018-2024
Summary Figure E: Global Market for OTC Antifungal Drugs, by Type, 2018-2024
Figure 1: Schematic of Fungi Classification
Figure 2: Worldwide Distribution of Reported Cases of C. auris, 2018
Figure 3: Number of Reported Cryptococcosis Cases, 1998-2017
Figure 4: Global Burden of HIV-Related Cryptococcal Meningitis, by Region
Figure 5: County-Specific Incidence of Histoplasmosis for the 12 U.S. States for Which Surveillance Data Were Available, 2011-2014
Figure 6: Timeline of Antifungal Drug Development, 1950-2020
Figure 7: Sphingolipid Biosynthetic Pathways
Figure 8: Strategic Approach to the Development of Vaccines for Fungal Infections
Figure 9: Principle Categories of Vaccines for Fungal Infections
Figure 10: Mycovia Pharmaceuticals: Current Product Pipeline
Figure 11: Ibrexafungerp Development Pipeline, 2018-2020
Figure 12: Global Market for Antifungal Drugs, by Segment, 2018-2024
Figure 13: Global Market Shares of Antifungal Drugs, by Segment, 2019
Figure 14: Global Market Shares of Antifungal Drugs, by Region, 2019
Figure 15: North American Market for Prescription Antifungal Drugs, by Type, 2019
Figure 16: North American Market for OTC Antifungal Drugs, by Type, 2019
Figure 17: Mutual Recognition Procedure
Figure 18: Decentralized Procedure
Figure 19: European Market for Prescription Antifungal Drugs, by Type, 2019
Figure 20: European Market for OTC Antifungal Drugs, by Type, 2019
Figure 21: Flowchart of New Drug Development and Approval Process in Japan
Figure 22: Timeline of the Standard Process of New Drug Approvals in Japan
Figure 23: Chinese Drug Funding/Reimbursement Approval Procedure
Figure 24: The Chinese Healthcare System
Figure 25: Asia-Pacific Market for Prescription Antifungal Drugs, by Type, 2019
Figure 26: Asia-Pacific Market for OTC Antifungal Drugs, by Type, 2019
Figure 27: Argentinian Regulatory Drug Approval Procedure, Standard Review 120-240 Business Days for Approval
Figure 28: Latin American Market for Prescription Antifungal Drugs, by Type, 2019
Figure 29: Latin American Market for OTC Antifungal Drugs, by Type, 2019
Figure 30: Current Structure of the Healthcare Sectors in Saudi Arabia, 2018
Figure 31: Middle Eastern/African Market for Prescription Antifungal Drugs, by Type, 2019
Figure 32: Middle Eastern/African Market for OTC Antifungal Drugs, by Type, 2019

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Anacor Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • Bausch Health Companies Inc.
  • Bayer Ag
  • Cidara Therapeutics Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Enzon Pharmaceuticals, Inc.
  • Ferrer Internacional S.A.
  • Galderma Pharma S.A.
  • Gilead Sciences Inc.
  • Glenmark Pharmaceuticals Ltd.
  • Janssen Pharmaceuticals Inc. (Johnson & Johnson)
  • Leadiant Biosciences Inc.
  • Merck & Co., Inc.
  • Merz Pharma Gmbh & Co. Kgaa
  • Moberg Pharma Ab
  • Mylan Laboratories Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Taro Pharmaceutical Industries Ltd.
  • Teva Pharmaceuticals Industries Ltd.
Note: Product cover images may vary from those shown
Adroll
adroll